Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression
B-lymphoblastic lymphoma (B-LBL) is a rare, aggressive non-Hodgkin lymphoma. Primary cutaneous involvement is extremely uncommon, contributing to diagnostic delays, treatment challenges and poor prognosis. We report a 53-year-old woman with relapsed/refractory primary cutaneous B-LBL who, after multiple treatments, achieved rapid and durable systemic regression via chimeric antigen receptor T-cell (CAR-T) therapy.
Authors
- W. Zhang
- Ailin Zhao (ORCID: https://orcid.org/0000-0002-5362-4824)
- Xinai Gan (ORCID: https://orcid.org/0009-0002-0166-2180)
- Yi-Xiang Wang (ORCID: https://orcid.org/0000-0002-5246-5497)
- Wenqing Yao
- M. Su
- Ting Niu
- Yijun Wu
- Xu Sun
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1093/bjd/ljaf484
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00